Gaggin Hanna K, Januzzi James L
Cardiology Division, Massachusetts General Hospital, 55 Fruit Street, Yawkey 5700, Boston, MA, USA.
Biochim Biophys Acta. 2013 Dec;1832(12):2442-50. doi: 10.1016/j.bbadis.2012.12.014. Epub 2013 Jan 9.
Heart failure (HF) biomarkers have dramatically impacted the way HF patients are evaluated and managed. B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are the gold standard biomarkers in determining the diagnosis and prognosis of HF, and studies on natriuretic peptide-guided HF management look promising. An array of additional biomarkers has emerged, each reflecting different pathophysiological processes in the development and progression of HF: myocardial insult, inflammation and remodeling. Novel biomarkers, such as mid-regional pro atrial natriuretic peptide (MR-proANP), mid-regional pro adrenomedullin (MR-proADM), highly sensitive troponins, soluble ST2 (sST2), growth differentiation factor (GDF)-15 and Galectin-3, show potential in determining prognosis beyond the established natriuretic peptides, but their role in the clinical care of the patient is still partially defined and more studies are needed. This article is part of a Special Issue entitled: Heart failure pathogenesis and emerging diagnostic and therapeutic interventions.
心力衰竭（HF）生物标志物极大地影响了HF患者的评估和管理方式。B型利钠肽（BNP）和N末端proBNP（NT-proBNP）是确定HF诊断和预后的金标准生物标志物，关于利钠肽指导HF管理的研究前景广阔。一系列其他生物标志物也已出现，每种都反映了HF发生和发展过程中的不同病理生理过程：心肌损伤、炎症和重塑。新型生物标志物，如中段心房利钠肽前体（MR-proANP）、中段肾上腺髓质素前体（MR-proADM）、高敏肌钙蛋白、可溶性ST2（sST2）、生长分化因子（GDF）-15和半乳凝素-3，在确定预后方面显示出超越既定利钠肽的潜力，但其在患者临床护理中的作用仍部分未明，还需要更多研究。本文是名为：心力衰竭发病机制及新兴诊断和治疗干预的特刊的一部分。
